Drug Profile
Research programme: prostaglandin E synthase inhibitors - Gesynta Pharma
Alternative Names: OX-MPI programmeLatest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator Biolipox
- Developer Biolipox; Boehringer Ingelheim; Gesynta Pharma
- Class Anti-inflammatories
- Mechanism of Action Prostaglandin-E synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Vascular disorders
- Discontinued Fever; Osteoarthritis; Pain; Rheumatoid arthritis
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for research development in Vascular-disorders in Sweden (PO)
- 13 Mar 2018 Discontinued - Preclinical for Pain and Rheumatoid arthritis in Europe (unspecified route)
- 13 Mar 2018 Research in Vascular disorders in Sweden (unspecified route) (Orexo pipeline, Gesynta Pharma pipeline, March 2018)